Published in Curr Cancer Drug Targets on May 01, 2008
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol (2009) 2.15
FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J (2009) 2.11
Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A (2009) 2.04
WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol (2011) 2.00
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene (2011) 1.59
Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. J Nanobiotechnology (2015) 1.52
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood (2009) 1.52
Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med (2013) 1.48
Deregulation of FoxM1b leads to tumour metastasis. EMBO Mol Med (2010) 1.43
Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist (2011) 1.32
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res (2009) 1.31
Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat (2011) 1.30
Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget (2011) 1.26
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets (2010) 1.25
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res (2011) 1.23
Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21
miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med (2011) 1.21
Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets. Genome Res (2011) 1.20
Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res (2010) 1.17
Oxidative stress mediates radiation lung injury by inducing apoptosis. Int J Radiat Oncol Biol Phys (2012) 1.17
Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res (2011) 1.16
Chemopreventive potential of curcumin in prostate cancer. Genes Nutr (2009) 1.14
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12
cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J Biol Chem (2010) 1.11
Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS One (2009) 1.10
Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma. Laryngoscope (2011) 1.09
Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. Cancer Res (2011) 1.09
Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol (2013) 1.07
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget (2014) 1.05
Stress responses from the endoplasmic reticulum in cancer. Front Oncol (2015) 1.03
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget (2013) 1.03
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem (2009) 1.03
Molecular biology of pancreatic cancer. World J Gastroenterol (2011) 1.02
The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. J Biol Chem (2012) 1.02
Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One (2011) 1.01
AKT kinase pathway: a leading target in cancer research. ScientificWorldJournal (2013) 1.01
BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res (2009) 0.98
Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS One (2012) 0.98
Bimodal regulation of FoxO3 by AKT and 14-3-3. Biochim Biophys Acta (2011) 0.98
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One (2012) 0.97
The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol (2014) 0.96
PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res (2008) 0.96
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget (2014) 0.95
Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors. Steroids (2008) 0.95
Minireview: modulation of hormone receptor signaling by dietary anticancer indoles. Mol Endocrinol (2009) 0.94
Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci (2011) 0.94
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One (2012) 0.92
Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status. Invest New Drugs (2010) 0.92
Human umbilical cord blood cells protect oligodendrocytes from brain ischemia through Akt signal transduction. J Biol Chem (2011) 0.92
Quercetin may suppress rat aberrant crypt foci formation by suppressing inflammatory mediators that influence proliferation and apoptosis. J Nutr (2008) 0.91
Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget (2015) 0.91
Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology (2010) 0.91
Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Oncotarget (2014) 0.91
Sequencing the full-length of the phosphatase and tensin homolog (PTEN) gene in hepatocellular carcinoma (HCC) using the 454 GS20 and Illumina GA DNA sequencing platforms. World J Surg (2009) 0.90
Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene (2009) 0.89
Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells. PLoS One (2014) 0.89
TCR-induced Akt serine 473 phosphorylation is regulated by protein kinase C-alpha. Biochem Biophys Res Commun (2010) 0.88
PTEN increases autophagy and inhibits the ubiquitin-proteasome pathway in glioma cells independently of its lipid phosphatase activity. PLoS One (2013) 0.88
Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma. Oncotarget (2015) 0.87
miR-1236 down-regulates alpha-fetoprotein, thus causing PTEN accumulation, which inhibits the PI3K/Akt pathway and malignant phenotype in hepatoma cells. Oncotarget (2015) 0.87
Phosphoinositides in the hepatitis C virus life cycle. Viruses (2012) 0.86
Caveolin-1 regulates endothelial adhesion of lung cancer cells via reactive oxygen species-dependent mechanism. PLoS One (2013) 0.85
A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res (2014) 0.85
Overexpression of PTEN suppresses lipopolysaccharide-induced lung fibroblast proliferation, differentiation and collagen secretion through inhibition of the PI3-K-Akt-GSK3beta pathway. Cell Biosci (2014) 0.85
Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways. PLoS One (2013) 0.84
Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis (2011) 0.84
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
β-lapachone-Induced Apoptosis of Human Gastric Carcinoma AGS Cells Is Caspase-Dependent and Regulated by the PI3K/Akt Pathway. Biomol Ther (Seoul) (2014) 0.83
Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair. Front Oncol (2014) 0.83
Knockdown of AKT3 (PKBγ) and PI3KCA suppresses cell viability and proliferation and induces the apoptosis of glioblastoma multiforme T98G cells. Biomed Res Int (2014) 0.82
Autocrine activity of BDNF induced by the STAT3 signaling pathway causes prolonged TrkB activation and promotes human non-small-cell lung cancer proliferation. Sci Rep (2016) 0.82
Regulation of axonal growth and neuromuscular junction formation by neuronal phosphatase and tensin homologue signaling. Mol Biol Cell (2012) 0.81
Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.81
Curcumin cytotoxicity is enhanced by PTEN disruption in colorectal cancer cells. World J Gastroenterol (2013) 0.81
Radiation-induced upregulation of telomerase activity escapes PI3-kinase inhibition in two malignant glioma cell lines. Int J Oncol (2013) 0.81
Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. Curr Oncol (2012) 0.81
Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma. PLoS One (2015) 0.81
MicroRNAs in multiple myeloma and related bone disease. Ann Transl Med (2015) 0.81
Salvianolic acid A positively regulates PTEN protein level and inhibits growth of A549 lung cancer cells. Biomed Rep (2012) 0.81
MUFFINN: cancer gene discovery via network analysis of somatic mutation data. Genome Biol (2016) 0.80
Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects? BMC Cancer (2009) 0.80
Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARγ. PLoS One (2014) 0.80
Peroxisome proliferator-activated receptor gamma ligand-mediated apoptosis of hepatocellular carcinoma cells depends upon modulation of PI3Kinase pathway independent of Akt. J Mol Signal (2010) 0.79
Cyclic phosphatidic acid stimulates cAMP production and inhibits growth in human colon cancer cells. PLoS One (2013) 0.79
Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. World J Clin Oncol (2013) 0.79
Roles of PTEN with DNA Repair in Parkinson's Disease. Int J Mol Sci (2016) 0.79
TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling. Carcinogenesis (2011) 0.79
PDK1 inhibitors. Pharm Pat Anal (2012) 0.79
The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells. PLoS One (2015) 0.79
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). J Med Chem (2010) 0.79
Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner. Sci Rep (2016) 0.79
Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China. Int J Clin Exp Pathol (2015) 0.78
High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. Hered Cancer Clin Pract (2015) 0.78
Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy. Int J Mol Sci (2015) 0.78
Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis. Cancer Biol Ther (2015) 0.78
Chronic infection by Leishmania amazonensis mediated through MAPK ERK mechanisms. Immunol Res (2014) 0.78
PTEN, more than the AKT pathway. Carcinogenesis (2007) 2.70
High content screening: seeing is believing. Trends Biotechnol (2010) 2.63
Pericytes and the pathogenesis of diabetic retinopathy. Diabetes (2002) 2.31
Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci (2004) 2.03
Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. Am J Pathol (2003) 1.74
The PKB/AKT pathway in cancer. Curr Pharm Des (2010) 1.67
Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes (2004) 1.59
Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle (2011) 1.53
Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle (2011) 1.45
Protein localization in disease and therapy. J Cell Sci (2011) 1.42
The PIM family of serine/threonine kinases in cancer. Med Res Rev (2013) 1.17
PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood (2011) 1.10
Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis (2006) 1.03
Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J Biol Chem (2009) 1.03
Understanding FOXO, new views on old transcription factors. Curr Cancer Drug Targets (2010) 1.01
Genetic diversity in recent elite faba bean lines using AFLP markers. Theor Appl Genet (2003) 0.97
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Res (2008) 0.97
Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. Chembiochem (2008) 0.97
Cooperation between Cdk4 and p27kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res (2005) 0.96
An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev Technol (2007) 0.95
Components and regulation of nuclear transport processes. FEBS J (2014) 0.94
A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Cytometry A (2010) 0.94
Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther (2007) 0.94
MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis (2007) 0.93
PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis (2008) 0.92
MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis (2007) 0.92
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem (2007) 0.91
Down-regulation of spinophilin in lung tumours contributes to tumourigenesis. J Pathol (2011) 0.89
Two clusters of residues at the docking groove of mitogen-activated protein kinases differentially mediate their functional interaction with the tyrosine phosphatases PTP-SL and STEP. J Biol Chem (2001) 0.88
Targeting nucleocytoplasmic transport in cancer therapy. Oncotarget (2014) 0.88
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One (2010) 0.87
Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis (2008) 0.87
The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis (2012) 0.86
Characterization of the p53 response to oncogene-induced senescence. PLoS One (2008) 0.86
Imaged-based high-throughput screening for anti-angiogenic drug discovery. Curr Pharm Des (2010) 0.86
Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. BMC Cell Biol (2009) 0.86
MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Carcinogenesis (2007) 0.86
Overexpression of cyclin D1 inhibits TNF-induced growth arrest. J Cell Biochem (2003) 0.85
Genetic modelling of the PTEN/AKT pathway in cancer research. Clin Transl Oncol (2008) 0.85
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anticancer Drugs (2005) 0.84
ERK2 shows a restrictive and locally selective mechanism of recognition by its tyrosine phosphatase inactivators not shared by its activator MEK1. J Biol Chem (2005) 0.83
A dual-color fluorescence-based platform to identify selective inhibitors of Akt signaling. PLoS One (2008) 0.83
Moving to the core: spatiotemporal analysis of Forkhead box O (FOXO) and nuclear factor-κB (NF-κB) nuclear translocation. Traffic (2013) 0.83
Inhibiting PI3K as a therapeutic strategy against cancer. Clin Transl Oncol (2009) 0.82
Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. Haematologica (2012) 0.82
Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR. Bioorg Med Chem Lett (2012) 0.81
Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors. Bioorg Med Chem Lett (2012) 0.81
Quantitative genetic analysis of embryo heterosis in faba bean (Vicia faba L.). Theor Appl Genet (2010) 0.80
Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker. Cancer Lett (2005) 0.80
Hybrid embryos of Vicia faba develop enhanced sink strength, which is established during early development. Plant J (2011) 0.79
Discovery of 14-3-3 protein-protein interaction inhibitors that sensitize multidrug-resistant cancer cells to doxorubicin and the Akt inhibitor GSK690693. ChemMedChem (2014) 0.78
Image-based high-throughput screening for inhibitors of angiogenesis. Methods Mol Biol (2013) 0.78
Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor. Bioorg Med Chem Lett (2012) 0.78
The therapeutic potential of FOXO proteins. Curr Drug Targets (2011) 0.78
A novel cyclometallated Pt(II)-ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation. Metallomics (2014) 0.78
Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. PLoS One (2013) 0.78
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases. Invest New Drugs (2012) 0.77
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis (2007) 0.77
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors. Bioorg Med Chem Lett (2012) 0.77
An integrated one-step system to extract, analyze and annotate all relevant information from image-based cell screening of chemical libraries. Mol Biosyst (2010) 0.77
Context-dependent therapeutic potential of FOXO proteins in oral squamous cell carcinoma. Oral Oncol (2011) 0.76
High-content screening of natural products reveals novel nuclear export inhibitors. J Biomol Screen (2013) 0.76
Special Review: Caught in the Crosshairs: Targeted Drugs and Personalized Medicine. Cancer J (2015) 0.76
Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. BMC Cancer (2014) 0.76
Regulation of MAPK cascades by protein tyrosine phosphatases. Methods Mol Biol (2004) 0.75
Image-based identification of nuclear export inhibitors from natural products. Methods Mol Biol (2015) 0.75
Meeting report: trends and challenges in high content analysis. Biotechnol J (2007) 0.75